{"name":"Faculdade de Ciências Médicas da Santa Casa de São Paulo","slug":"faculdade-de-ci-ncias-m-dicas-da-santa-casa-de-s-o-paulo","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"sugammadex ED90","genericName":"sugammadex ED90","slug":"sugammadex-ed90","indication":"Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults undergoing surgery","status":"marketed"}]}],"pipeline":[{"name":"sugammadex ED90","genericName":"sugammadex ED90","slug":"sugammadex-ed90","phase":"marketed","mechanism":"Sugammadex is a selective relaxant binding agent that encapsulates and inactivates rocuronium and vecuronium neuromuscular blocking agents, rapidly reversing neuromuscular blockade.","indications":["Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults undergoing surgery"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}